163 related articles for article (PubMed ID: 37928273)
1. CENPA functions as a transcriptional regulator to promote hepatocellular carcinoma progression via cooperating with YY1.
Liao J; Chen Z; Chang R; Yuan T; Li G; Zhu C; Wen J; Wei Y; Huang Z; Ding Z; Chu L; Liang J; Zhang B
Int J Biol Sci; 2023; 19(16):5218-5232. PubMed ID: 37928273
[TBL] [Abstract][Full Text] [Related]
2. The role of the histone H3 variant CENPA in prostate cancer.
Saha AK; Contreras-Galindo R; Niknafs YS; Iyer M; Qin T; Padmanabhan K; Siddiqui J; Palande M; Wang C; Qian B; Ward E; Tang T; Tomlins SA; Gitlin SD; Sartor MA; Omenn GS; Chinnaiyan AM; Markovitz DM
J Biol Chem; 2020 Jun; 295(25):8537-8549. PubMed ID: 32371391
[TBL] [Abstract][Full Text] [Related]
3. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
4. CENPA promotes glutamine metabolism and tumor progression by up-regulating SLC38A1 in endometrial cancer.
Li S; Zhang Z; Li Z; Yang L; Liu J; Liu Y; Liu Y; Hou Y; Mei M; Huang Y
Cell Signal; 2024 May; 117():111110. PubMed ID: 38382691
[TBL] [Abstract][Full Text] [Related]
5. The Oncogenic Role of CENPA in Hepatocellular Carcinoma Development: Evidence from Bioinformatic Analysis.
Zhang Y; Yang L; Shi J; Lu Y; Chen X; Yang Z
Biomed Res Int; 2020; 2020():3040839. PubMed ID: 32337237
[TBL] [Abstract][Full Text] [Related]
6. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
7. Twist1-YY1-p300 complex promotes the malignant progression of HCC through activation of miR-9 by forming phase-separated condensates at super-enhancers and relieved by metformin.
Meng J; Han J; Wang X; Wu T; Zhang H; An H; Qin L; Sun Y; Zhong W; Yang C; Liu H; Sun T
Pharmacol Res; 2023 Feb; 188():106661. PubMed ID: 36669583
[TBL] [Abstract][Full Text] [Related]
8. Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha.
Zhang S; Jiang T; Feng L; Sun J; Lu H; Wang Q; Pan M; Huang D; Wang X; Wang L; Jin H
J Mol Med (Berl); 2012 Sep; 90(9):1069-77. PubMed ID: 22391813
[TBL] [Abstract][Full Text] [Related]
9. LINC00205, a YY1-modulated lncRNA, serves as a sponge for miR-26a-5p facilitating the proliferation of hepatocellular carcinoma cells by elevating CDK6.
Cheng T; Yao Y; Zhang S; Zhang XN; Zhang AH; Yang W; Hou CZ
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6208-6219. PubMed ID: 34730201
[TBL] [Abstract][Full Text] [Related]
10. YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
Dong S; Ma X; Wang Z; Han B; Zou H; Wu Z; Zang Y; Zhuang L
Oncotarget; 2017 Jun; 8(25):40583-40593. PubMed ID: 28489564
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
12. YY1 Complex Promotes Quaking Expression via Super-Enhancer Binding during EMT of Hepatocellular Carcinoma.
Han J; Meng J; Chen S; Wang X; Yin S; Zhang Q; Liu H; Qin R; Li Z; Zhong W; Zhang C; Zhang H; Tang Y; Lin T; Gao W; Zhang X; Yang L; Liu Y; Zhou HG; Sun T; Yang C
Cancer Res; 2019 Apr; 79(7):1451-1464. PubMed ID: 30760518
[TBL] [Abstract][Full Text] [Related]
13. Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation.
Li Y; Kasim V; Yan X; Li L; Meliala ITS; Huang C; Li Z; Lei K; Song G; Zheng X; Wu S
Theranostics; 2019; 9(25):7599-7615. PubMed ID: 31695789
[TBL] [Abstract][Full Text] [Related]
14. LINC01608 activated by YY1 facilitate hepatocellular carcinoma progression by modulating the EGFR/ERK axis.
Han M; Liu F; Li X; Zhang H; Pan Y; Liu Y; Zhu H; Liang H; Chen X; Liao Z; Zhang Z; Zhang B
Liver Int; 2023 Feb; 43(2):471-489. PubMed ID: 36385489
[TBL] [Abstract][Full Text] [Related]
15. Molecular interplay between linc01134 and YY1 dictates hepatocellular carcinoma progression.
Rong Z; Wang Z; Wang X; Qin C; Geng W
J Exp Clin Cancer Res; 2020 Apr; 39(1):61. PubMed ID: 32272940
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic relevance of CP2c and YY1 expression in hepatocellular carcinoma.
Kim JS; Son SH; Kim MY; Choi D; Jang IS; Paik SS; Chae JH; Uversky VN; Kim CG
Oncotarget; 2017 Apr; 8(15):24389-24400. PubMed ID: 28412749
[TBL] [Abstract][Full Text] [Related]
17. LncRNA LINC00668 promotes cell proliferation, migration, invasion ability and EMT process in hepatocellular carcinoma by targeting miR-532-5p/YY1 axis.
Xuan W; Zhou C; You G
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32249890
[TBL] [Abstract][Full Text] [Related]
18. Study on the mechanism of LOXL1-AS1/miR-3614-5p/YY1 signal axis in the malignant phenotype regulation of hepatocellular carcinoma.
Feng Z; Ye Z; Xie J; Chen W; Li W; Xing C
Biol Direct; 2021 Dec; 16(1):24. PubMed ID: 34863279
[TBL] [Abstract][Full Text] [Related]
19. YY1 lactylation in microglia promotes angiogenesis through transcription activation-mediated upregulation of FGF2.
Wang X; Fan W; Li N; Ma Y; Yao M; Wang G; He S; Li W; Tan J; Lu Q; Hou S
Genome Biol; 2023 Apr; 24(1):87. PubMed ID: 37085894
[TBL] [Abstract][Full Text] [Related]
20. Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways.
Chen H; Wu F; Xu H; Wei G; Ding M; Xu F; Deivasigamani A; Zhou G; Hui KM; Xia H
Cancer Gene Ther; 2022 Jul; 29(7):1033-1042. PubMed ID: 34857915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
